109
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer

, , , , , , , , & ORCID Icon show all
Pages 9305-9318 | Published online: 22 Dec 2021

References

  • Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640. doi:10.1016/j.mayocp.2019.01.01331378236
  • Wang BY, Huang JY, Cheng CY, Lin CH, Ko J, Liaw YP. Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol. 2013;8(9):1128–1135. doi:10.1097/JTO.0b013e31829ceba423945383
  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.2165433433946
  • Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.1105831454018
  • Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa160677427718847
  • Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464–1472. doi:10.6004/jnccn.2019.005931805526
  • Shih JY, Inoue A, Cheng R, Varea R, Kim SW. Does pemetrexed work in targetable, nonsquamous non-small-cell lung cancer? A narrative review. Cancers (Basel). 2020;12(9):Sep. doi:10.3390/cancers12092658
  • Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three Phase 3 trials. Lung Cancer. 2012;76(2):222–227. doi:10.1016/j.lungcan.2011.10.02122115704
  • Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the Phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–2902. doi:10.1200/JCO.2012.47.110223835707
  • Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011;74(1):132–138. doi:10.1016/j.lungcan.2011.01.02421367480
  • Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011;104(10):1594–1601. doi:10.1038/bjc.2011.12921487406
  • Krawczyk P, Kucharczyk T, Kowalski DM, et al. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res Clin Oncol. 2014;140(12):2047–2057. doi:10.1007/s00432-014-1756-625028118
  • Li WJ, Jiang H, Fang XJ, et al. Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett. 2013;5(4):1165–1170. doi:10.3892/ol.2013.117523599757
  • Park S, Park TS, Choi CM, et al. Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements. Clin Lung Cancer. 2015;16(5):e83–9. doi:10.1016/j.cllc.2015.01.00325682546
  • Wu SG, Yang CH, Yu CJ, et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer. 2011;72(3):333–339. doi:10.1016/j.lungcan.2010.10.01221111508
  • Wu MF, Hsiao YM, Huang CF, et al. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol. 2010;5(8):1143–1151. doi:10.1097/JTO.0b013e3181e0b95420559153
  • Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15(12):712–729. doi:10.1038/nrc402726597527
  • Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol. 2013;34(4):2041–2051. doi:10.1007/s13277-013-0842-8
  • Rossi E, Bernabeu C, Smadja DM. Endoglin as an adhesion molecule in mature and progenitor endothelial cells: a function beyond TGF-beta. Front Med (Lausanne). 2019;6:10. doi:10.3389/fmed.2019.0001030761306
  • Vidal AC, Duong F, Howard LE, et al. Soluble endoglin (sCD105) as a novel biomarker for detecting aggressive prostate cancer. Anticancer Res. 2020;40(3):1459–1462. doi:10.21873/anticanres.1408832132043
  • Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.08127189322
  • Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem. 2012;393(5):301–317. doi:10.1515/hsz-2011-026022505514
  • Schoonderwoerd MJA, Goumans MTH, Hawinkels L. Endoglin: beyond the endothelium. Biomolecules. 2020;10(2):Feb. doi:10.3390/biom10020289
  • Tian H, Huang JJ, Golzio C, et al. Endoglin interacts with VEGFR2 to promote angiogenesis. FASEB J. 2018;32(6):2934–2949. doi:10.1096/fj.201700867RR29401587
  • Paauwe M, Heijkants RC, Oudt CH, et al. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. Oncogene. 2016;35(31):4069–4079. doi:10.1038/onc.2015.50926804178
  • Apolo AB, Karzai FH, Trepel JB, et al. A Phase II clinical trial of TRC105 (Anti-Endoglin Antibody) in adults with advanced/metastatic urothelial carcinoma. Clin Genitourin Cancer. 2017;15(1):77–85. doi:10.1016/j.clgc.2016.05.01027328856
  • Choueiri TK, Michaelson MD, Posadas EM, et al. An open label Phase Ib dose escalation study of TRC105 (Anti-Endoglin Antibody) with axitinib in patients with metastatic renal cell carcinoma. Oncologist. 2019;24(2):202–210. doi:10.1634/theoncologist.2018-029930190302
  • Davidson B, Stavnes HT, Forsund M, Berner A, Staff AC. CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. Breast. 2010;19(6):493–498. doi:10.1016/j.breast.2010.05.01321078485
  • Kauer J, Schwartz K, Tandler C, et al. CD105 (Endoglin) as negative prognostic factor in AML. Sci Rep. 2019;9(1):18337. doi:10.1038/s41598-019-54767-x31797971
  • Paauwe M, Schoonderwoerd MJA, Helderman R, et al. Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis. Clin Cancer Res. 2018;24(24):6331–6344. doi:10.1158/1078-0432.CCR-18-032929945992
  • O’Leary K, Shia A, Cavicchioli F, et al. Identification of Endoglin as an epigenetically regulated tumor-suppressor gene in lung cancer. Br J Cancer. 2015;113(6):970–978. doi:10.1038/bjc.2015.30226325105
  • Okamoto I, Aoe K, Kato T, et al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs. 2013;31(5):1275–1282. doi:10.1007/s10637-013-9941-z23475281
  • Schuette WH, Groschel A, Sebastian M, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013;14(3):215–223. doi:10.1016/j.cllc.2012.10.00123332288
  • Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247–255. doi:10.1016/S1470-2045(12)70063-322341744
  • Castonguay R, Werner ED, Matthews RG, et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem. 2011;286(34):30034–30046. doi:10.1074/jbc.M111.26013321737454
  • Jiang X, Yang B, Lu J, Zhan Z, Li K, Ren X. Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. Tumor Biol. 2015;36(2):861–869. doi:10.1007/s13277-014-2692-4